Mutant-selective degradation by BRAF-targeting PROTACs

Over 300 BRAF missense mutations have been identified in patients, yet currently approved drugs target V600 mutants alone. Moreover, acquired resistance inevitably emerges, primarily due to RAF lesions that prevent inhibition of BRAF V600 with current treatments. Therefore, there is a need for new t...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Nat Commun
Glavni autori: Alabi, Shanique, Jaime-Figueroa, Saul, Yao, Zhan, Gao, Yijun, Hines, John, Samarasinghe, Kusal T. G., Vogt, Lea, Rosen, Neal, Crews, Craig M.
Format: Artigo
Jezik:Inglês
Izdano: Nature Publishing Group UK 2021
Teme:
Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7876048/
https://ncbi.nlm.nih.gov/pubmed/33568647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41467-021-21159-7
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items